## AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

## **Listing of Claims:**

1-145. (Cancelled)

146. (Currently Amended) An isolated mammalian cell, wherein said cell endogenously expresses Hox11 (Hox11(+)) and lacks expression of CD45 (CD45(-)), and wherein said cell is obtained from spleen or mobilized into peripheral blood from the spleen.

147. (Cancelled)

- 148. (Previously Presented) The cell of claim 146, wherein said cell expresses one or more cell markers selected from CD90, CD44, and CD29, but does not express CD34.
- 149. (Currently Amended) The cell of claim 146, wherein said cell is obtained from <u>said</u> spleen or peripheral blood or tissue of a mammal by a method comprising:
  - a) separating cells from said <u>spleen or peripheral blood or tissue</u> into a first cell population which predominantly expresses CD45 antigen on the surface of said cells and a second cell population which predominantly does not express CD45 antigen on the surface of said cells; and
  - b) selecting said second cell population and further separating Hox11(+) cells from said second cell population to obtain at least one Hox11(+), CD45(-) cell.
- 150. (Previously Presented) The cell of claim 149, wherein said at least one Hox11(+), CD45(-) cell expresses one of more cell surface markers selected from CD90, CD44, and CD29, but does not express.

151-158. (Cancelled)

- 159. (Currently Amended) The cell of claim 146151, wherein said cell is a splenocyte.
- 160. (Currently Amended) The cell of claim <u>146</u>158, wherein said cell is obtained from bone marrow or <u>said</u> peripheral blood.
- 161. (Previously Presented) The cell of claim 146, wherein said cell can differentiate into two or more different cell types.
  - 162. (Previously Presented) The cell of claim 146, wherein said cell is a human cell.